OR WAIT null SECS
© 2024 MJH Life Sciences™ and BioPharm International. All rights reserved.
Netherlands-based biopharmaceutical company OctoPlus N.V. has started pharmaceutical production in its new manufacturing facility in Leiden. The facility has received a license from the Dutch authorities to manufacture pharmaceutical products according to international good manufacturing practice (GMP) guidelines.
Netherlands-based biopharmaceutical company OctoPlus N.V. has started pharmaceutical production in its new manufacturing facility in Leiden. The facility has received a license from the Dutch authorities to manufacture pharmaceutical products according to international good manufacturing practice (GMP) guidelines.
OctoPlus began expanding its headquarters in November 2006. The new building comprises offices, laboratories, and a GMP manufacturing plant that produces final drug product for the company’s clients.
With the expansion, OctoPlus has more than doubled its manufacturing capacity and the company can now produce clinical scale Phase 1, 2, and 3 and even small-scale commercial supplies of injectable pharmaceutical products and other complex formulations.